Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of oral IAG933 in advanced mesothelioma and Hippo pathway-altered solid tumors
NL-OMON54125Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IAG933 in mesothelioma, Nonhematologic neoplasms and epithelioid hemangioendothelioma (EHE) (4 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Dose-limiting toxicities and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
IAG933
03
Conditions
mesotheliomaNonhematologic neoplasmsepithelioid hemangioendothelioma (EHE)
Beyond the preview
Go deeper on NL-OMON54125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54125.